文献速递肝病消化道肿瘤与早癌

肝功能失代偿是接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者死亡的主要驱动因素:成功抗病毒治疗的影响

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
PubMed 文献 · Hepatology · 2024-07-19

基于AB-real观察性研究(n=898)中571例接受一线阿替利珠单抗+贝伐珠单抗治疗的晚期/不可切除、Child-Pugh A级肝细胞癌患者,中位随访11.0个月(95%CI:5.1-19.7)期间,293例(51.3%)发生肿瘤进展无失代偿,94例(16.5%)发生肝功能失代偿。多变量时间依赖性分析显示,失代偿(HR:19.04,95%CI:9.75-37.19)和肝细胞癌进展(HR:9.91,95%CI:5.85-16.78)均与总生存独立相关;基线ALBI 2/3级(sHR:3.35,95%CI:1.98-5.67)与失代偿独立相关,病毒性病因具有保护作用(sHR:0.55,95%CI:0.34-0.87),病毒性病因患者中有效抗病毒治疗与较低失代偿风险显著相关(sHR:0.48,95%CI:0.25-0.93)。结论认为肝功能失代偿识别了AB治疗后预后最差的患者,在基线ALBI>1和非病毒性病因患者中更常见,有效抗病毒治疗可能保护免于失代偿。

要点

  • AB治疗后肝功能失代偿(HR:19.04)和肿瘤进展(HR:9.91)均与总生存独立相关。
  • 基线ALBI 2/3级与失代偿独立相关(sHR:3.35),病毒性病因具有保护作用(sHR:0.55)。
  • 病毒性病因患者中有效抗病毒治疗与较低失代偿风险显著相关(sHR:0.48)。

核心结论

  • 肝功能失代偿识别了接受阿替利珠单抗联合贝伐珠单抗治疗后预后最差的患者,且在基线ALBI>1和非病毒性病因患者中更常见。
  • 有效抗病毒治疗可能保护免于失代偿,突显了非病毒性病因患者的预后劣势以及多学科管理以最大化总生存的重要性。

研究设计与样本

  • 来自AB-real观察性研究(n=898),纳入571例晚期/不可切除、Child-Pugh A级、接受一线阿替利珠单抗+贝伐珠单抗治疗的肝细胞癌患者。
  • 采用时间依赖性Cox模型分析随访期间肝功能失代偿和肿瘤进展与总生存的关系。
  • 采用竞争风险分析评估基线特征作为失代偿的预测因素。

主要发现

  • 中位随访11.0个月(95%CI:5.1-19.7)期间,293例(51.3%)发生肿瘤进展无失代偿,94例(16.5%)发生肝功能失代偿。
  • 多变量时间依赖性分析中,失代偿(HR:19.04,95%CI:9.75-37.19)、肝细胞癌进展(HR:9.91,95%CI:5.85-16.78)、ALBI 2/3级(HR:2.16,95%CI:1.69-2.77)和结节数>3个(HR:1.63,95%CI:1.28-2.08)与总生存独立相关。
  • 基线ALBI 2/3级与失代偿独立相关(sHR:3.35,95%CI:1.98-5.67),病毒性病因具有保护作用(sHR:0.55,95%CI:0.34-0.87)。
  • 病毒性病因患者中,有效抗病毒治疗与较低失代偿风险显著相关(sHR:0.48,95%CI:0.25-0.93)。

临床怎么用

  • 作者认为肝功能失代偿识别了AB治疗后预后最差的患者,在基线ALBI>1和非病毒性病因患者中更常见。
  • 作者认为有效抗病毒治疗可能保护免于失代偿,并强调多学科管理以最大化总生存的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation over tumor progression in influencing overall survival (OS) has not been assessed in combination immunotherapy recipients. APPROACH AND RESULTS: From the AB-real observational study (n = 898), we accrued 571 patients with advanced/unresectable hepatocellular carcinoma, Child-Pugh A class treated with frontline atezolizumab + bevacizumab (AB). Hepatic decompensation and tumor progression during follow-up were studied in relationship to patients' OS using a time-dependent Cox model. Baseline characteristics were evaluated as predictors of decompensation in competing risks analysis. During a median follow-up of 11.0 months (95% CI: 5.1-19.7), 293 patients (51.3%) developed tumor progression without decompensation, and 94 (16.5%) developed decompensation. In multivariable time-dependent analysis, decompensation (HR: 19.04, 95% CI: 9.75-37.19), hepatocellular carcinoma progression (HR: 9.91, 95% CI: 5.85-16.78), albumin-bilirubin (ALBI) grade 2/3 (HR: 2.16, 95% CI: 1.69-2.77), and number of nodules >3(HR: 1.63, 95% CI: 1.28-2.08) were independently associated with OS. Pretreatment ALBI grade 2/3 (subdistribution hazard ratio [sHR]: 3.35, 95% CI: 1.98-5.67) was independently associated with decompensation, whereas viral etiology was protective (sHR: 0.55, 95% CI: 0.34-0.87). Among patients with viral etiology, effective antiviral treatment was significantly associated with a lower risk of decompensation (sHR: 0.48, 95% CI: 0.25-0.93). CONCLUSIONS: Hepatic decompensation identifies patients with the worst prognosis following AB and is more common in patients with baseline ALBI >1 and nonviral etiology. Effective antiviral treatment may protect from decompensation, highlighting the prognostic disadvantage of patients with nonviral etiologies and the importance of multidisciplinary management to maximize OS.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Celsa C, Cabibbo G, Fulgenzi CAM, et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology. 2024. PMID: 39028886. doi:10.1097/HEP.0000000000001026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。